<SEC-DOCUMENT>0001193125-15-260580.txt : 20150723
<SEC-HEADER>0001193125-15-260580.hdr.sgml : 20150723
<ACCEPTANCE-DATETIME>20150723080053
ACCESSION NUMBER:		0001193125-15-260580
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20150723
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150723
DATE AS OF CHANGE:		20150723

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INOTEK PHARMACEUTICALS CORP
		CENTRAL INDEX KEY:			0001281895
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36829
		FILM NUMBER:		151001243

	BUSINESS ADDRESS:	
		STREET 1:		131 HARTWELL AVE
		STREET 2:		1ST FLOOR, SUITE 105
		CITY:			LEXINGTON
		STATE:			MA
		ZIP:			02421
		BUSINESS PHONE:		781-676-2100

	MAIL ADDRESS:	
		STREET 1:		131 HARTWELL AVE
		STREET 2:		1ST FLOOR, SUITE 105
		CITY:			LEXINGTON
		STATE:			MA
		ZIP:			02421
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d55313d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) of The Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of Earliest Event Reported): July&nbsp;23, 2015 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:22pt; font-family:Times New Roman" ALIGN="center"><B>Inotek Pharmaceuticals Corporation </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DELAWARE</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>001-36829</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>04-3475813</B></P></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(State or other jurisdiction of <BR>incorporation)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Commission File Number)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(I.R.S. Employer<BR>Identification No.)</B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>131 Hartwell Avenue, Suite 105</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Lexington, MA</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>02421</B></P></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>Registrant&#146;s telephone number, including area code <B>(781)&nbsp;676-2100 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former
name or former address, if changed since last report) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;8.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Other Events. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;23, 2015, Inotek Pharmaceuticals Corporation (the &#147;Company&#148;)
issued a press release summarizing the results of the Company&#146;s meeting with representatives from the U.S. Food and Drug Administration (the &#147;FDA&#148;). The End-of-Phase 2 meeting with the FDA was held to discuss the Company&#146;s Phase
3 program for <I>trabodenoson</I> monotherapy. A copy of this press release is filed herewith as Exhibit 99.1. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements and Exhibits </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">Exhibits. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:39.10pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit&nbsp;No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release, dated July&nbsp;23, 2015</TD></TR>
</TABLE> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: July&nbsp;23, 2015</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="3"><B>INOTEK PHARMACEUTICALS CORPORATION</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Dale Ritter</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dale Ritter</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Vice
President&#151;Finance</P></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:39.10pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit&nbsp;No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release, dated July&nbsp;23, 2015</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d55313dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g55313g23z07.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Inotek Pharmaceuticals Announces
Positive End-of-Phase 2 Meeting with FDA and Phase 3 Development Strategy for Trabodenoson, a Novel Treatment for Glaucoma </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>&#151;Pivotal Studies Designed to Show Superiority to Placebo&#151; </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>&#151;1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> Phase 3 Study to Commence in 4Q15 with Top-line Data In 2016&#151;
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>&#151;Conference Call Scheduled for 8:30AM ET&#151; </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Lexington, MA &#151; July&nbsp;23, 2015 &#151;</B> Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical-stage biopharmaceutical company focused on
the discovery, development and commercialization of therapies for ocular diseases, today announced the Phase 3 development strategy of its lead glaucoma drug, trabodenoson, a first-in-class selective adenosine mimetic designed to restore the
eye&#146;s natural pressure control mechanism. Based on feedback from a recent End of Phase 2 meeting with the US Food and Drug Administration (FDA), Inotek is in final preparation stages to commence its first Phase 3 trial to support a New Drug
Application (NDA) for trabodenoson. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Our End-of-Phase 2 meeting was a critical milestone for advancing the development of trabodenoson. We are
pleased with the agency&#146;s guidance on the pivotal trial design which will enable a more efficient registration path to potentially bring this novel glaucoma therapy to market for the benefit of patients,&#148; said David P. Southwell, President
and Chief Executive Officer.&nbsp;&#147;We expect to commence our first Phase 3 trial in 4Q and look forward to data in 2016.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The trial design for
the first pivotal study is a five-arm superiority trial that will include three doses of trabodenoson. These doses were selected to optimize lowering of intraocular pressure while maintaining the good tolerability observed in Phase 2 trials. The
primary efficacy endpoint of the study is the reduction of intraocular pressure (IOP), statistically superior as compared to placebo. A comparator arm of timolol will also be included for study validation, but not for statistical comparison. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;There is a major unmet medical need for a well-tolerated and effective therapy with a new mechanism of action for glaucoma,&#148; said Rudolf
Baumgartner, M.D, Chief Medical Officer of Inotek. &#147;Our overall program will consist of three clinical trials encompassing a total subject exposure of 1300 patients. Our previous Phase 2 studies have demonstrated that trabodenoson&#146;s
efficacy improves over time, and with increases in dose. A benefit of the Phase 3 superiority design is that we can investigate more than one dose of trabodenoson, allowing us to further optimize the drug&#146;s clinical and safety profile.&#148;
</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g55313g23z07.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In Phase 2 trials, trabodenoson demonstrated a dose-response for intraocular pressure lowering in ocular
hypertension and primary open angle glaucoma patients. After 14 days of treatment, both the 200mg and 500mg doses of trabodenoson demonstrated a statistically significant reduction (P&lt;0.05) in IOP relative to the matched placebo group. After 28
days of treatment, the 500mg dose continued to demonstrate a statistically significant reduction in IOP relative to placebo, in the range of other glaucoma therapies. Across all trials, the efficacy of trabodenoson has remained consistent, with no
waning effect observed, and the IOP reduction was consistent across different patient sub-populations. Trabodenoson has also been well tolerated with no serious adverse events. In patients with glaucoma or ocular hypertension, the rate of
conjunctival hyperemia (redness in the eye), a side-effect commonly associated with other mechanisms used to treat glaucoma, was not affected by trabodenoson treatment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">William McVicar, Ph.D., Chief Scientific Officer, commented, &#147;Glaucoma is an optic nerve neuropathy, where vision is lost due to the death of the retinal
ganglion cells which carry the visual signal from the retina to the brain. While trabodenoson data indicated IOP reductions in the range of current therapies, we have also demonstrated in animals that trabodenoson can protect these neural cells from
high ocular pressure injury. This data supports that A1 agonism not only reduces IOP but may also have a neuroprotective role in the retina. If we are able to demonstrate the same neuroprotective effects of trabodenoson in humans, we believe
trabodenoson has the potential to significantly change how glaucoma is managed, potentially supporting earlier intervention in a substantially larger population of patients.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conference Call Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inotek will host a
conference call and webcast today, July&nbsp;23, 2015, at 8:30 am (EDT) to discuss the trabodenoson development strategy. To participate in the conference call, please dial (866)&nbsp;430-2017 (U.S.) or (704)&nbsp;908-0413 (international) five
minutes prior to the start of the call and provide the Conference ID: 93395336, or access the listen-only webcast by visiting the Company&#146;s website <U>www.inotekpharma.com</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An archive of today&#146;s conference call will be available shortly after the conclusion of the call and accessed by dialing (855)&nbsp;859-2056 (U.S.) or
(404)&nbsp;537-3406 and referencing the Conference ID: 93395336, or by visiting Inotek&#146;s website. The audio replay will be available for two weeks following the call and the webcast for thirty days. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Inotek Pharmaceuticals Corporation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inotek
Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for glaucoma and other other eye diseases. Our lead product candidate, trabodenoson, is a first-in-class selective
adenosine mimetic developed in Inotek&#146;s laboratories designed to restore the eye&#146;s natural pressure control mechanism. The development of trabodenoson </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g55313g23z07.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
monotherapy delivered in a once-daily eye drop formulation will be followed by a fixed-dose combination of trabodenoson with latanoprost<I>. </I>Additionally, the Company is evaluating the
potential for selective adenosine mimetics to address optic neuropathies and other degenerative retinal diseases. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements, which are subject to substantial risks, uncertainties and assumptions. You should not place reliance on
these statements. Forward-looking statements include information concerning the proposed offerings. These statements often include words such as &#147;believe,&#148; &#147;expect,&#148; &#147;anticipate,&#148; &#147;intend,&#148; &#147;plan,&#148;
&#147;estimate,&#148; &#147;seek,&#148; &#147;will,&#148; &#147;may&#148; or similar expressions. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such
outcomes. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements,
whether as a result of new information, future events or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Inotek Contact: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Claudine Prowse, Ph.D. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vice President, Strategy and Investor
Relations Officer </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">cprowse@inotekpharma.com </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">781-552-4305
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Contact: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MacDougall Biomedical </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Karen Sharma </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>ksharma@macbiocom.com </U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">781.235.3060 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g55313g23z07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g55313g23z07.jpg
M_]C_X0`817AI9@``24DJ``@``````````````/_L`!%$=6-K>0`!``0```!D
M``#_X0,K:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B`\
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835`@0V]R92`U+C,M8S`Q,2`V-BXQ-#4V-C$L(#(P,3(O,#(O,#8M
M,30Z-38Z,C<@("`@("`@("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<#TB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87`O,2XP+R(@>&UL;G,Z>&UP34T](FAT='`Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]M;2\B('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C`O<U1Y<&4O4F5S;W5R8V52968C(B!X;7`Z0W)E
M871O<E1O;VP](D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I(B!X;7!-
M33I);G-T86YC94E$/2)X;7`N:6ED.C5&-S4Y0T8W,S!"13$Q134X,C-%13E$
M0S!#-4$W,S%"(B!X;7!-33I$;V-U;65N=$E$/2)X;7`N9&ED.C5&-S4Y0T8X
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M(G(B/S[_[@`.061O8F4`9,`````!_]L`A``!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`@("`@("`@("`@(#`P,#`P,#`P,#
M`0$!`0$!`0(!`0("`@$"`@,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P/_P``1"`!&`/H#`1$``A$!`Q$!_\0`MP``
M`0,%`0$```````````````$&"`($!0<)`PH!`0`!!0$!```````````````&
M`0(#!`4'"!```0($!`0#!04""`\!`````0(#`!$$!2$2!@<Q01,(42(R87&!
M%!61H;%""7(C4F*2,S14%A?!\8*RTD-3<Y.C)'15E7<9$0`!`P($!`,$"`4%
M```````!``(#$00A,1(%05%A!G$B$X$R%`>1H;'!T4(C,^%R4S0(\/%2HA7_
MV@`,`P$``A$#$0`_`/OX@B((B"(@B((B"(@B((B"()`!),@,23P`\8(L,]?*
M-A3G4#W2;0I?60VIQM829'*4@X`\^$;3+.:0#33432G%<V7=;.$D2.H`*UIA
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M`(RI2/MB7;?;1@>K0:1E7GS7G>]7KZ"T83J(\W0<DQ4K4VHEMQ:)3.9)()''
M''C'5..!H:J--JW%I+:<EB*;4=SJ*]5,[7.FE45(0D$@@IG+&-R7;[>.#U&L
M'JYE<N'>]PENS!)*3;DT`XCVK+I6I*PO.YU$DJ2X%D+2ODI*@9@QI\*<"NFX
M5P-2X<2MF:9OSZD)S...NM234M.N%1>:'!2<Q.5Q(])\8X-]9QM?@`&.R(X%
M3/9K]\T.EYI.S`^'/Q6[+->&JQIM"G,^::6G5>4J4GBTZ/RO)'\H<(B=W:.B
M)<!0<1]XZ+T#;MQ$S1%*?U>!Y^/5.&-%=A$$1!$01$$1!$01$$1!$01$$1!$
M01$$1!$01),3E,3E.7.7C!$L$1!$01$$1/ES$$1,#B93,A[_``]\$1!%A[Z[
MT;<ZZ70TVA2"^2<N9F<EH"ORE0/'PC;L6:[@-I4G+Q7.W60QV+WAP:`,>&"C
MK>]4%54^W1J2ZIMQ;'S!ETT-HP2EE/`)2/#C$XM=NTL!FPZ?BO*KS>ZDLMC5
MV6H\/!:<KJNXTUQ?><?4ZMY74!<F4+2?RB?IRQ*H(K>6V:P-`:,,,UYQ=W%[
M:WSY9'ESW&N.1Z*[^N4ZZ9TN?N'P@IDKTJ41R/MC%\"]LHT^:.JVSN\#K9Q?
MY)J4Z&J;+3I9=0\5!(2X'"HF0DHXX\Q(QTG-UM+.8HN"UPC+9:Y&M4YZF^-I
M2!2`.+4@'.?YM,^.//&.9'8N)K-@T'+BN]/O#&BEJ*O(SX*FP5=Q^H*K6JE2
M,B9+*B>DYSZ>7@`(NOH[<0"!S1CES'56[//?"]-VQYH!CR/1;NTMJ1+U4BF?
M*:53C;BG%*,F'2VVLH(')U*A@1C$2O[`B(R,\S1PXYKT?;]ZCED$<Q$<O/@>
M7MY*0=$I2Z2F4MQ+JE,H*G$\%$I!G]\0B8`2N#105R7J]N7.@87&ITBI]BN2
M0.)`]YE&)9DF9)P"DD^\01501$$1!$014E209%0!.,B901*"#P(/N,X(E@B(
M(B"(@B0$&<B#(R,N1\#!$!0)(!!(P,N7O@B6"*"SO='JM'>^[VR"PVS^RK6C
M;?J'ZV5.?4UU59;TUBFP,W3Z3:SEE**5QHLFD>GK-:J<Z22D$B1/+X^\Q58U
M5!$01>;BR@)(`,UH29^"C(_&"+GM<.^6SZ-[L]0=O6Y%/;M/:=6Q:D:3U=UB
M@?5;@@%NDNQ6KILLU"_(E>`"N,6UQHLOIDLU#-.WO`[G-4=O7]TO]FK1:+T-
M>ZLI[-7KKE.%M-$MVD0KY%32A^^=14YDJ)*<(J3148P/!QH5-:E?-0TRX4Y2
MY3L/$3X%U`44_P"23%5C3"U=4/%5;2"2D/M(9FJ1#:7$$+"$'RYU^)Q'*._M
M<;*-DR<#7Q40WXNDF=`3Y"S)1M=06776ER3TG%HQ(&`)D?:3$Y#M8#AC4+R9
M\?I/,9PTDK`7PT:Z=<WVB\SYFPDA2E#FD`$\HZ%B)1)@WR%<;=76SX=1</6;
MB/!<[^^SO'M7:1M?8+O:+"->;M;D:JMNB]H=K6:@4]UUM?[E4)IBJF&5:DVZ
MVN+!J7996TF9PCA]^=Y#L+:8MQ9%%<[A/=1P1Q.D].ID-"ZN-=-1AQ)`4C^4
M?RRN?G-W!<;5ZYV[M3;;5]UN.X.;JBM(8QJ\V7ZD@KZ;<W$44(M5]X'ZNNC-
M+7W5FHOTX;$;'I2T.W^^(MNZUFN=P%KH&OF*_P"GVVBZU7752:<$I::2I9D9
M".3-WC\PK6%]R_M^$M8TDZ;ECB0,3I:*DFG`5*]2VSY0_P"*>]WUOL]C\V)3
M<7<K8H@_;)HV:WFC-<CZ-8VM*N<0WF5U"[9NX'27<ML7MQO+I1U@4>L;,RY=
MK;3/?-*TMJ=F3=\TI<'``4W*QU4VW4D`@\8G&R[E#O\`M46]6M!'*VI;6NEW
MYFGD6FH(/)>#=\=L[A\N.\[_`+#WIK_C+&X+(Y"W2+B`_M7+!_3F;YFG(J6]
ML51-,M,M/-*PS.3(!*B.8F.<:5P)GR%[VFG!;MD;:*`11.!?Q\4X;4VIVXTB
M!F/3=#TTXY2CGS!!\.!C2G?Z<#W89478L81/=L8<16OT*3FF:A;P7,!,Z=M:
MT))R*=*L7$HE^[F,)#G$!W.(1D'K]7WKUW8IGOUL).D9+3?<MK3??1>C[;<-
MAM"6W7.I'KD&[C17-U;3-';DME:Z@)2M!4HD2XX1R#7@I-&&D^<T7.'9[OF[
MU-XM6W&P::V.TG5LZ2U!26;7*T5-0VY:`NJ#%8$%;LEN,(!4#PPB@)*R.C8T
M8G$KM33+?6PPNH;#3RZ=E;S8,PV^I`+K8,\0A1(BY8%<01$$2*,@2/9^,$7*
M_N'[P^X?2/<>YL+LAME8-;W)-CHKHPS<'7FZM_KTJZNI?+B'$MML,-HD0<8M
M)-:+,V-I9J)6\^V+=#NTUQJ6_4/<#M%9MO;#26]MZT7"W5+KCM37%S*NF6EQ
M:PM.7&8BH)XJU[6#W#53=$R`3@2!,>V6,56-+!$01>#[I90XL)"LC+KLN$RV
MDJ`GRG*"+G%LOWSG4-#W$ZDW9IK)I?2FR]Z>HZ.MH7BBHN2$.U3;-NZ;RRJH
MN#IID@9!+SCE%H.=5F=&`6AIS6S.T'?;>+N%H=4;AZNT-;M%[7UM86]LDD/I
MOUZH4+*55M:V\1)@I'E6$A*C.6`BH)*M>UK<!FIKS/ARGQY^$56-<>WP?_US
MJ_\`Y?8R/=]#;!^^+?S+,1^B/%=@T>D?'\3%RPJJ"(@B\*CTH_WK?^<((N"^
MYFQVD.X3]13=G;K5YJV6Z[;]JIL=THW%-OV6]4U"'**O1E*2M+;LB1%F;J+8
MJ61!PSJHU;YZ\WKTU?\`9OM?WNLBZN_;7;EVQW2>NU*<<3J72%774;-O<#SD
M_F^@RR!FF5)X'A%#48*]FDU<#F,E].EN,Z:E/C0T9_Y28R+43#U7_3'OVJ;\
M(D6V?M#VJ'[S_>^S[E%W5%+6U5WJW:914QFDEM"LN50X\#C./0=MFABM6LE_
M<YT7B^^V]U/N,LD!)M\@!ABF<ZR\R5==I:1ZE$I)P'&1E*.PQ[7TT$%1J2*2
M*IE:10<<5PP[O+A;-I?U1>U'>SN#:5JK8#5EEJ-O=BWEMK^B[$[RU0%+6ZEU
M!F0:1TZM==2U3A:II4<PX1Y5WM<;?LO>=AO'=D)N^WWAD,`],O;!<N<VDCFY
M.J2VCL2VFJGE7TE\K[6[[R_QI[P[/^7!%IWS:7(O-V:"/4W;;&^9D$..H?#`
M%SR!0C`YKL_?;A1Z2M-_U3JJ\VNU::L%FN=WU!=+A=:)-!26>GHGGJQZJ4NH
M*4L+IIIF<!F$>RW%U;0Q/FN"!`T$N)P%!B2:TI3/%?&-JT[M<0[=MD,EQ?7,
MK(X8F,<7OD<X!C6@-Q.K&G1<B/T>+1<ZBP]RF[.F;97Z([8]VM[=1W7M]VHN
M;K]35:9;HZE;&J=44]2^A'S%KUM<C\U3+3-'3,A@(\R^6\,K[#<-RM6.@V"Y
MO'.MH75):!4/>"?RRN\PIA1?8G^4E[:6_<O;7:V\RQ[A\S-JV&"+==PC:UK)
MW.%;:`L!.F2TC_3D!QU8G-=J6*:I=5^Y:<G_``I%((/PD8G;Y8V#SD+YZCMY
MY#^FQV?@MD:'8JZ6XN?-N3#S1#2"K,4*`DKCCC$>WJ2&:`>B,0<5->UH+B"]
M<ZZ-0YOE'VJ3VDO4[_VK/XF(%N_Y5Z[V_P"](G95%61R1(E3U!D#($Y,)^[E
M'$4H7(O]-53G]Z'=P2M1EN#4$S)P6*NH,Y<)XQ:W,K-+[K?!=?4^E/[(_"+E
MA54$1!%2OTGX?B((N"?<AI+=G6?ZC?T?9G<:CVMUBK1%$ZWJBMR+9:I6[2ZJ
MH9Z*YAU3S0*0F1G%A][!;#"!%YA45737M4T-OWH:T:DH]^-Z;5N[=JRO;=LM
M3;4I3]*HTIRK:6B042XK'P$7"O%8GEI]T4"ES%58B"(@BLZS^9?EQ^5J)?\`
M#5!%\FC^W&OKMJ7>_<RDMR]7;6[;[NHNFY&AVJE]!N-O-V><^H.TS)D^REIL
MI5,'*,8QYK<!TT&1.2^FS8+<_;W=K:_2>KMLE43>E'K934=-:Z0--'3[U*TA
MM=H?IFO*RNG(D,!F$CSB\8K6>-.!SJMUQ56*,2NU_1B^Y9[N95=;L=7NZ?H]
M.JM(*/I88HZ,4;3_`/M.ITA,\IQ2F-5>7^0,ZJ3B0$@`<!_CBJL2P1$$5"T!
M8`)(DI*L/XIF!!%&*U=KNC;5W(7KN39NUW<U5>;*FS/VA91]+:3T@R7V\>H5
MEL<.`BE,:J_6=&C@LGO]VT;=]P-+IE6KV7J.\Z/O5'>;#J*W(;1=*4TU2V^N
M@4\4YW**I4T,R2<.(@154:XMR4A*9@,---@J/39:8!5+$,H"`J0X%0$55J96
MKK>OHUM?Y\J6$+04`J`6V"`VM`QFXHB1'`QV]KG&ML.%2[BHIOUM,W5>-%6!
MA49'`M+KN<*2YU5]1*L%(7/%!]HB?4P'*B\@+W%Y<:ZB<5@;[4]-GY8)2IQT
M#//BAOE_*C>L8JO]4X-&7BN3N]T!&+84+W#'H%%3N9[;]L>Z?:.\;.;JVBHK
M]*76OH+H%6U]=%=;5=[:OJV^ZVJX,RJ*&MI'3F0M!!!BSN#MS:.[MN_\??O5
M-D)6R@QO,;@]AJTZAC05-1Q&"IV=WIW'\L>Y8>]NR)&P=P6['1U+0]CXY,'Q
MR,/E>QXP(.!7-.M_0P[6;A0/6^Z[C=R%WM=8PFEN-IK]Y-755'<*-4@]1UM.
M]7+:?IWT#*I"@4D<HBI^4W9TM8Y9MQ=&<"#<2$.'(BM*%>^-_P`U/GK:Z;JU
MM.V([AAU,+-JMFOC=P<UP8"'#,$8KKKMSM_IC:S;[1&V^CK:FV:6T%INVZ8T
MY0$!3E):;6TEJD;=<D"\]D'F6?,HXF)[;6\%A;,V^R!;91-#&"M?*!0?4%\T
M[C?WN_[O=]R;TX2;[N%R^XG?2FJ60U<0.`KD!@."W;:JL5=,G`!QKR.(&!,A
M@K#&1CDW4)BEIFTXA23;KHW%N!E(S`_BG%:$/.7*C#""XX7?,E()*6>+KI`X
MI0D$_"-*<-]!Y<:-I_LNK9REEVQS02X'AFI36"WJI$]7*0A=.T@*5@ITCS=0
M(F<B"DX#C'GE_<"9U.(/T=%[/L]K)`TR/%`\`A9]QI+HDJ<BA:"`93#B<IG\
M(YR[:C+L'VO:.V"U#N;J'3-WNUSJ=S+X[>KHS<2@M4#CCJW2Q29<5-YW#BK&
M*`45[GEP`/!2>`D`/``?9%58E@B((D(F)>[\8(N?O<!^G[M[OWN<_NE<=>:W
MTCJ-Z@H:%TZ8JTTLDT;199<0\%)=1G:5)209&+2!FLK9'4#1D$\^VSLXL';C
MJ&]:AM.Y&O\`6C]YMS=O-'JNY+K*2F:2Z5EYIM;BQURL^KC*`%$D<79BBF>,
M`!.?M\8N6)+!$01>3K274K0HF2VUMF6'E6DI,O;(P11:V5[4-![,U^ZU7;ZV
MX:D8W8KW:J_6V^(:=HFJ6H-0IRWMM`%+K*OF5B:O-(Q0!9'2$@`"E%9["=I.
MCNW?6FMM0Z"U+J-%@UFHN*T+5O!>GK,[U5.ERW-@C(X%*(G*>60@!3+)4<\O
MQ=[REM%58B"(@B((B"(@B((B"(@BQUUIW:FC<;9`4L%*^FHR#H09ELGEF_&,
M]L]D<H<_+[.JTMP@DN+5T<1\Y^OHM#W_`$TV\\XZXGI.O.+=;J$IDE2U3FT\
MD2R.H(D0>/*)E97[FLT@U8!E^!XKS>_VB"5QU#1/S'/J%I&X:>KTW*H;K7`E
M&8971CU&APR^Z)=!N$!MFNA'FIER*\SNMFO1?O9=$!E?>'$=%>"WT[5,ZRT@
M34VH%PXK49<9GG&#XF1TK7O.`.7!;8LH66[HHQYBW/BF?3-*<JFV053ZLCQ]
M*3C\8[,C@V(OX448B8Y\K8OS%U/H*=]5;::J2`4]-:4@)<0)'#Q\08XT5U+$
M:UJTG)2>YL+>X%"-+P,PET]IVY.W)26W4HIDH_>O@3"APRR_A2BZ^O[86XU`
MF4G`*FS;+>27I:'`6[1B>:WOI73J*=YJHI4J"@EQH.J$W7UJ;*2&QR:;G-2C
MA$/W"]<YA;(<,Z<`*\>O)>F[9M4,4@9;-_5/YCB?9TYK=E*VMFG9:<5G6AM*
M5J\5`8_9$0D<UTA<T4:2O186.CB:QQJX"B]EJ2A"EK4E"4@DJ40E*1XDG`"+
M%E5#3S3B`XAUI:%&06VM*D$^`4"03.'VHJ\PFK%,D^HS'E.,P?#""*A;[+:%
M.+=;0VDR+BUI2C@#ZR9<X9HE0ZVM"5I6A25@95)6E25?LJ!D8(JLPQQ!(X@$
M$CV&"),R""O,C*)S5,2`'&9X"4$7BU54[C:G$OTY0@E*EH>0I"9<E*!D#!*J
MMM]IQ`6AQM:22D%M84%&<@`0<28(D<J:=J74?:1,R&=Q*03PD"2,8(:\%Z!Q
M!23G09"9.82`XS)Y""*AI]EY)4T\TZE)(4IM:5@$<B4DR,$586@C,%)*<!F!
M&4^R<Y3@BI=>99REUUIK,K*GJ+2C,3R3,B:L((O68\?;\/&"(@B((B"(@B((
MB"(@B((B"+`7BT-5:''4,I<<4@AUJ>4/``E*@K\KS9Q2?A&[:W3H2&$T;7`\
MOX%<K<=N9<M,D8'K4^G^/):5U+IFKJ&2^P&E*ITJ6EQQUMDK:&"FE(40>LW*
M1\3$LL+Z,/T.J`X]3CS\%YWO.VRR1ZV`>O&*TXTXBG-:]8M5P?/DIEI'-3@*
M4R\1/B#'9?<01^\X5Z*,0V5W-^W&0.N"\6=#W&GJUUO686#,I8P&4JYSC(_>
MH)(A#I(/-8(NU+V&X-V'M<,PSE[5[?2;CU4M&E6%N*"4K.#*23(*<<."$S^V
M+6SP.:7!XH!7JLTEG=QN#9(SJ/+);8T[I5ZG0PP^A`S'.[T7$N&J4<>F@MSR
MMI'J4981'+W<6.<9&UZ5PIU4UVG:W0QM@`_4=B?'E^*W%04#=&VGRIZF0).4
M`(;3QZ30Y)!^),1:>=TSN.G_`%B5/K*R9:Q@9R4Q/W!9&-=;R;6K6:A^Q5C-
M*TMYYSII2TV2DN#.)I41B$$<?9%0:&JH:TP3/<L]YH:.@2R135-7<J=U%*P5
M.4M$E"$A6?\`A9N?MAFE#3JO5WZ]3,ZD9<:=JJZY5C-+2*9"D-)IW&@AUY!X
M-E*"?=**)3!8[Y.\&RTMD=HGG'[9<FD-IJ'%+;K:8B<WW9S4DJ)$YQ6M":9)
MB<TCE%<U61JFIVZNEKF[T[6KI&5KZ;#=+-2:9M9]33V7#QG!4IACFKJU5=[H
MVKU<:BEJU5=X9;JJ.B6E133NRZ0ITX^68QA3"O!5KA7BK9BGO-'::VSOTM:4
M%]FXN*0\MQYVD=5GK:=#G$*3R'A`T"IBKVYBV/:>KOH%-4L-I>I%5/[IQ*<J
M5`+!0HE2B)>:7&&(-.*KUXK(&J:IFM/7)`6:"E+J:Q5(TO(E2V9-YF?41GAT
MXI7BL8Y0O5=EIG7Z6H67[^BI9S%?5%,I\G.H<4ME/+P@![50@4IP5Y=Z>O4=
M0HIT5/RZ7J'JMM%06[1-A)=;I/`X8@<8J"*A,0>BN4U5`S::U>F[?4JJ*D-T
M8:R.-@K=`0I9*CY5H0HDGQBAQ5?#--]"+G:[(Y;*UFL2+7<*:I0\A:WW7J1:
MLRR5@DK""92BH^M*8++ZCJ65+MU[I$/URVVAT+:MIPLUTR)I;E@V^D'B8"AP
M*KU6P.LO^KJ_HG6Y>O\`J_[7W1:BNX(B"(@B((B"(@B((B"(@B((L>OZ9U7.
MI\KU,AZN?)Z9>;-F\OOYQF'Q&D4U::X+5=\'ZAU:/4IC6F28E=1VE;P4;RPR
MT6O^G;%`ZO*P5'*%+2)*2G\O##V1VX);L-H(JGC5P'VJ-3P;>Z4EDX:W@`QQ
MH/$!6'R%G_\`/T__`*U[_1C8]>[_`*'_`';^*P?#6-?[DU_D=^"S=GI;6T]F
M-T8JV>H)M*HULI+Y2<F=;@R],#T\I\XTKJ2Z<PCT]+J9AP.'@%MV,.W,N`3,
M'NK@"TC'VA/-CY'JK^7Z'5_-T\LY<Y2PEXRCDO\`6T#770I)'\/K/I:=?17D
M85G1!$AY<)^W[Y01(<N8>G-[99OAS@BJ@BH,I\4\IYA,RGAC,2QX01`RYL"C
MW`#-]H/^"")3+Q$^4QB/O@B!+QGA^;U2F9SGC*?P@BH3T,JLO2Z?YLN3+.9G
MFEAQAXHD'R_2PZ/1YRR=+V_Q8(.B]/))/IE+R\)2E^7V2@B!EQEEESE+[_A!
M%0V&Y'IEN4S/I!(3FGC.4_-!$*"/S%$L9]0">6?":I2'O@B!T<J,O2"?]5++
,EGRR2P^R"+U@B__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
